Cargando…
Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs
BACKGROUND: The duration of treatment (DOT) of the initial intervention and subsequent treatment is the key to determining the accuracy of anticancer-drug budget impact analysis (BIA) calculations. However, existing studies only use simple assumptions as a proxy for DOT, resulting in a high degree o...
Autores principales: | Ma, Yue, Zhou, Jiting, Ye, Yuxin, Ma, Aixia, Li, Hongchao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259044/ https://www.ncbi.nlm.nih.gov/pubmed/37303057 http://dx.doi.org/10.1186/s12962-023-00447-7 |
Ejemplares similares
-
Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
por: Ma, Yue, et al.
Publicado: (2021) -
The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
por: Ma, Yue, et al.
Publicado: (2023) -
Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency
por: Nevens, Hilde, et al.
Publicado: (2019) -
Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis
por: Wei, Qiran, et al.
Publicado: (2023) -
The Stanford Data Miner: a novel approach for integrating and exploring heterogeneous immunological data
por: Siebert, Janet C, et al.
Publicado: (2012)